Perkins Coie Advises Attune Medical in Acquisition by Haemonetics

CHICAGO (March 6, 2024)—Perkins Coie is pleased to have advised Chicago-based Attune Medical in its definitive acquisition agreement with Haemonetics Corporation, a global medical technology company focused on delivering innovative medical products and solutions.

Haemonetics will acquire Attune Medical for an upfront cash payment of $160 million at closing plus additional contingent considerations. Attune Medical is the manufacturer of the ensoETM proactive esophageal cooling device, the only FDA-cleared temperature regulation device indicated for esophageal protection during radiofrequency cardiac ablation procedures. The device significantly reduces the likelihood of esophageal injury during such procedures that are used to treat atrial fibrillation, a condition that affects millions of people across the United States.

The Perkins Coie advisory team on this acquisition was led by corporate law partner John Schreiner and included emerging companies and venture capital law counsel Matt Klomparens; corporate and securities counsel Brandon Kaster; and corporate and securities associate Betul Serbest. The Perkins Coie team, including corporate partner Steve Ducommun, has a longstanding relationship with Attune Medical and has served as their legal advisor on various matters for over a decade, since the inception of ensoETM.

For more information, please see Haemonetic's press release here.